Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment

doi:10.3389/fimmu.2021.635371

. 2021 Mar 11:12:635371.

doi: 10.3389/fimmu.2021.635371. eCollection 2021.

Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment

Miguel Angel Martinez¹

Affiliations

PMID: 33777024
PMCID: PMC7990901
DOI: 10.3389/fimmu.2021.635371

Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment

Miguel Angel Martinez. Front Immunol. 2021.

. 2021 Mar 11:12:635371.

doi: 10.3389/fimmu.2021.635371. eCollection 2021.

Author

Miguel Angel Martinez¹

Affiliation

¹ IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.

PMID: 33777024
PMCID: PMC7990901
DOI: 10.3389/fimmu.2021.635371

No abstract available

Keywords: COVID-19; HCV; HIV; repurposed drugs; treatment efficacy.

PubMed Disclaimer

Conflict of interest statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Cited by

Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review.
de Matos PH, da Silva TP, Mansano AB, Gancedo NC, Tonin FS, Pelloso FC, Petruco MV, de Melo EB, Fernandez-Llimos F, Sanches ACC, de Mello JCP, Chierrito D, de Medeiros Araújo DC. de Matos PH, et al. Inflamm Res. 2022 Dec;71(12):1489-1500. doi: 10.1007/s00011-022-01642-7. Epub 2022 Oct 28. Inflamm Res. 2022. PMID: 36307652 Free PMC article.
Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity.
Wimalawansa SJ. Wimalawansa SJ. Heliyon. 2024 Jul 17;10(15):e34691. doi: 10.1016/j.heliyon.2024.e34691. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39166024 Free PMC article. Review.
In vitro testing and computational analysis of specific phytochemicals with antiviral activities considering their possible applications against COVID-19.
Ristovski JT, Matin MM, Kong R, Kusturica MP, Zhang H. Ristovski JT, et al. S Afr J Bot. 2022 Dec;151:248-258. doi: 10.1016/j.sajb.2022.02.009. Epub 2022 Feb 10. S Afr J Bot. 2022. PMID: 35165493 Free PMC article.
Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example.
Imami AS, McCullumsmith RE, O'Donovan SM. Imami AS, et al. Transl Psychiatry. 2021 Nov 16;11(1):591. doi: 10.1038/s41398-021-01724-w. Transl Psychiatry. 2021. PMID: 34785660 Free PMC article. Review.
Key patient demographics shape innate immune topography in noncritical hypoxic COVID-19 pneumonia.
Billi AC, Wasikowski R, Ma F, Yalavarthi S, Hoy CK, Zuo Y, Patrick MT, Shah N, Parker C, Aaronson C, Harbaugh A, Lucido MF, Shedden K, Rao K, IglayReger HB, Burant CF, Kahlenberg JM, Tsoi LC, Gudjonsson JE, Knight JS, Kanthi Y. Billi AC, et al. JCI Insight. 2023 Aug 22;8(16):e166110. doi: 10.1172/jci.insight.166110. JCI Insight. 2023. PMID: 37606044 Free PMC article.

See all "Cited by" articles

References

1. Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. (2020) 64:e00399–20. 10.1128/AAC.00399-20 - DOI - PMC - PubMed
1. Martinez MA. Clinical trials of repurposed antivirals for SARS-CoV-2. Antimicrob Agents Chemother. (2020) 64:e01101–20. 10.1128/AAC.01101-20 - DOI - PMC - PubMed
1. Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, et al. . A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19. Antimicrob Agents Chemother. (2020) 64:e01897–20. 10.1128/AAC.01897-20 - DOI - PMC - PubMed
1. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. . A Trial of Lopinavir–Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. (2020) 382:1787–99. 10.1056/NEJMoa2001282 - DOI - PMC - PubMed
1. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. . Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. (2020) 395:1569–78. 10.1016/S0140-6736(20)31022-9 - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations

[1] Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. (2020) 64:e00399–20. 10.1128/AAC.00399-20 - DOI - PMC - PubMed

[2] Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. (2020) 64:e00399–20. 10.1128/AAC.00399-20 - DOI - PMC - PubMed

[3] Martinez MA. Clinical trials of repurposed antivirals for SARS-CoV-2. Antimicrob Agents Chemother. (2020) 64:e01101–20. 10.1128/AAC.01101-20 - DOI - PMC - PubMed

[4] Martinez MA. Clinical trials of repurposed antivirals for SARS-CoV-2. Antimicrob Agents Chemother. (2020) 64:e01101–20. 10.1128/AAC.01101-20 - DOI - PMC - PubMed

[5] Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, et al. . A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19. Antimicrob Agents Chemother. (2020) 64:e01897–20. 10.1128/AAC.01897-20 - DOI - PMC - PubMed

[6] Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, et al. . A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19. Antimicrob Agents Chemother. (2020) 64:e01897–20. 10.1128/AAC.01897-20 - DOI - PMC - PubMed

[7] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. . A Trial of Lopinavir–Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. (2020) 382:1787–99. 10.1056/NEJMoa2001282 - DOI - PMC - PubMed

[8] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. . A Trial of Lopinavir–Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. (2020) 382:1787–99. 10.1056/NEJMoa2001282 - DOI - PMC - PubMed

[9] Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. . Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. (2020) 395:1569–78. 10.1016/S0140-6736(20)31022-9 - DOI - PMC - PubMed

[10] Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. . Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. (2020) 395:1569–78. 10.1016/S0140-6736(20)31022-9 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment

Affiliation

Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment

Author

Affiliation

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources